FilingSEC EDGAR8-K
Korro Bio submits application for Phase 1/2 clinical trial of KRRO-121
· SEC accepted
StagePhase 1/2 application
Filing content
The company submitted an application to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121 to treat hyperammonemia in patients with Urea Cycle Disorders.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…